Steady supply and distribution of brands that had previously been recalled continued to experience strong sales gains in 2016, according to Kline’s research for its annual Nonprescription Drugs USA study.
Johnson & Johnson’s Tylenol and Motrin brands, which had been off the market for several years, are making a substantial comeback supported by strong advertising and marketing. GlaxoSmithKline’s Excedrin brands was also temporarily off the market and enjoys steady gains in 2016 as it is in predictable supply with retailers again. All other major OTC pain reliever brands and store brands experience flat to declining sales in 2016 with the exception of Prestige Brands’ BC and Goody’s pain relief powders and Doan’s (Dr. Reddy’s Laboratories). (more…)
One area that shows much higher rates of growth than monograph OTC digestive products are brands that offer claims of improving digestive health and immunity. Probiotics, prebiotics, and digestive enzymes all offer prevention of digestive ailments, including constipation, and improve regularity. Many brands in these market segments are able to achieve high double-digit gains as they are used on a daily basis, and consumers, therefore, make frequent repeat purchases. Kline’s upcoming Digestive Health, Immunity, and Probiotics: U.S. Market Analysis and Opportunitiesstudy will contain complete analyses of this market and sales, growth, and market shares of the leading brands and companies. (more…)
Findings from our upcoming Nonprescription Drugs USA study estimate sales of topical OTC products in the United States at approximately $2.9 billion at the factory level, up 2.9% from 2015 sales levels.
Findings from our upcoming Nonprescription Drugs USA study estimate that sales of OTC sleeping aids post 3.4% growth to reach $244 million at the factory level in 2016.
After seeing significant growth rates ranging from 50.0% to 15.0% per year in the recent past, the market for OTC sleeping aids is still growing, but at a much slower pace. ZzzQuil (Procter & Gamble), Unisom (Sanofi), and private-label sleeping aids posted growth while the rest of the market was flat or declining in 2016. (more…)
Findings from our upcoming Nonprescription Drugs USA study estimate sales of the upper respiratory OTC market in the United States at approximately $6.0 billion at the factory level, up 1.6% from 2015 sales. (more…)
Foodservice distributors and chemical and machinery manufacturers alike can differentiate themselves by offering foodservice end users value-added services ranging from employee training assistance to information on the latest regulations of food safety to technology-enabled efficiency and labor-saving devices. End users in restaurants, hotels, and other foodservice settings are challenged to remain efficient, compliant, and profitable on a regular basis. Distributors or chemical suppliers that offer cleaning chemicals, tools, or machinery to help end users with these issues are seen as valued partners, and loyalty is developed as a result. For example, foodservice distributor Gordon offers a foodservice regulatory compliance program, including online training modules, webinars, and nutrition resources that helps keep their customers coming back to them. (more…)
The U.S. OTC market posted 2.2% growth overall from 2015 to 2016, according to Kline’s venerable Nonprescription Drugs USA annual market assessment study. However, topical analgesics, nasal allergy medications, herbal products, and contraceptive products posted much higher rates of dollar sales growth. The calendar year of 2016 was marked as being a weak cold and flu season, which put a damper on sales of many OTC upper respiratory brands and market segments. However, in contrast, nasal allergy sprays grew by double digits, driven by growth of newer Rx-to-OTC switch brands, Flonase Allergy Relief (GlaxoSmithKline), and the addition of Rhinocort Allergy Spray by Johnson & Johnson to the market. This rapid uptake of nasal allergy sprays resulted in a small decline in sales of oral allergy medications. (more…)
When considering a potential switch, the FDA is tasked with weighing the benefits of enhanced access against the incremental risks greater access will pose. In doing so, the FDA will generally consider the efficacy and safety profile of a drug based upon the studies conducted to gain Rx approval, as well as the clinical knowledge gained from first-hand experience of the product usage on the Rx marketplace. In addition, the FDA requires additional studies with consumers demonstrating that they can use the product safely in an OTC setting without third-party intervention. (more…)
Transparency, ingredients, and clear labeling are important to consumers of nutritional supplements and probiotics. These are also substantial to reputable manufacturers in these markets looking to educate consumers on product benefits and to distance their brands from products on the market with less science supporting their claims and benefits.
In January 2017, the Council for Responsible Nutrition and the International Probiotics Association collaboratively published “Best Practice Guidelines for Probiotics” as a proactive set of voluntary, scientifically-based guidelines to encourage responsible production and marketing of dietary supplements and functional foods that contain probiotics. (more…)
The industrial and institutional cleaning wipes market presents opportunities for companies to tap into this growing segment. All major end-use segments are expected to increase consumption of wipes, reflecting the need for superior cleaning products and to maintain clean and healthy facilities. The ease of use and convenience that wipes offer end users will contribute to future growth across all end-use segments, largely for general-purpose wipes. End-use segments, such as healthcare facilities, food service, and schools and universities, will continue to emphasize the importance of clean surfaces and hands in order to minimize germs and illness at their facilities. Wipes are expected to play a key role in this goal. (more…)